



2017 Medicare Part D Step Therapy Requirements

Effective: November 01, 2017

BISPHOSPHONATE THERAPY

Products Affected

- **FOSAMAX PLUS D 70 MG-2,800 UNIT TABLET**
- **FOSAMAX PLUS D 70 MG-5,600 UNIT TABLET**
- *risedronate 150 mg tablet*
- *risedronate 30 mg tablet*
- *risedronate 35 mg tablet*
- *risedronate 35 mg tablet (4 pack)*
- *risedronate 5 mg tablet*

Details

Criteria	PRIOR USE OF GENERIC ALENDRONATE WITHIN THE PREVIOUS 12 MONTHS.
-----------------	---

INVOKANA

Products Affected

- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET

Details

Criteria	PRIOR USE OF GENERIC METFORMIN, METFORMIN/GLIPIZIDE, METFORMIN/PIOGLITAZONE, OR JENTADUETO WITHIN THE PREVIOUS 12 MONTHS.
-----------------	---

JARDIANCE

Products Affected

- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR USE OF GENERIC METFORMIN, METFORMIN/GLIPIZIDE, METFORMIN/PIOGLITAZONE, OR JENTADUETO WITHIN THE PREVIOUS 12 MONTHS.
-----------------	---

LEVEMIR

Products Affected

- LEVEMIR 100 UNIT/ML
SUBCUTANEOUS SOLUTION
- LEVEMIR FLEXTOUCH 100
UNIT/ML (3 ML) SUBCUTANEOUS
INSULIN PEN

Details

Criteria	PRIOR USE OF LANTUS OR TOUJEO WITHIN THE PREVIOUS 12 MONTHS.
-----------------	--

OMEGA-3-ACID ETHYL ESTERS

Products Affected

- *omega-3 acid ethyl esters 1 gram capsule*
- *triklo 1 gram capsule*

Details

Criteria	PRIOR USE OF GEMFIBROZIL OR A FORMULARY FENOFIBRATE WITHIN THE PREVIOUS 12 MONTHS.
-----------------	--

RENIN INHIBITOR THERAPY

Products Affected

- *amlodipine 10 mg-valsartan 160 mg tablet*
- *amlodipine 10 mg-valsartan 160 mg-hydrochlorothiazide 12.5 mg tablet*
- *amlodipine 10 mg-valsartan 160 mg-hydrochlorothiazide 25 mg tablet*
- *amlodipine 10 mg-valsartan 320 mg tablet*
- *amlodipine 10 mg-valsartan 320 mg-hydrochlorothiazide 25 mg tablet*
- *amlodipine 5 mg-valsartan 160 mg tablet*
- *amlodipine 5 mg-valsartan 160 mg-hydrochlorothiazide 12.5 mg tablet*
- *amlodipine 5 mg-valsartan 160 mg-hydrochlorothiazide 25 mg tablet*
- *amlodipine 5 mg-valsartan 320 mg tablet*

Details

Criteria	PRIOR USE OF A FORMULARY ACE INHIBITOR (SUCH AS BENAZEPRIL, CAPTOPRIL, ENALAPRIL, LISINOPRIL, RAMIPRIL, BENAZEPRIL-HCTZ OR LISINOPRIL-HCTZ) OR OF A GENERIC FORMULARY ARB (SUCH AS LOSARTAN, LOSARTAN HCTZ, IRBESARTAN, IRBESARTAN-HCTZ) WITHIN THE PREVIOUS 12 MONTHS.
-----------------	---

ULORIC

Products Affected

- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria	PRIOR USE OF ALLOPURINOL WITHIN THE PREVIOUS 12 MONTHS.
-----------------	---

VASCEPA

Products Affected

- VASCEPA 0.5 GRAM CAPSULE
- VASCEPA 1 GRAM CAPSULE

Details

Criteria	PRIOR USE OF GEMFIBROZIL OR A FORMULARY FENOFIBRATE WITHIN THE PREVIOUS 12 MONTHS.
-----------------	--

ZOLPIDEM CR

Products Affected

- *zolpidem er 12.5 mg tablet, extended release, multiphase*
- *zolpidem er 6.25 mg tablet, extended release, multiphase*

Details

Criteria	PRIOR USE OF GENERIC ZOLPIDEM REGULAR RELEASE WITHIN THE PREVIOUS 12 MONTHS.
-----------------	--

Index

<i>amlodipine 10 mg-valsartan 160 mg tablet</i>	6	<i>risedronate 35 mg tablet</i>	1
<i>amlodipine 10 mg-valsartan 160 mg- hydrochlorothiazide 12.5 mg tablet</i>	6	<i>risedronate 35 mg tablet (4 pack)</i>	1
<i>amlodipine 10 mg-valsartan 160 mg- hydrochlorothiazide 25 mg tablet</i>	6	<i>risedronate 5 mg tablet</i>	1
<i>amlodipine 10 mg-valsartan 320 mg tablet</i>	6	SYNJARDY 12.5 MG-1,000 MG TABLET	3
<i>amlodipine 10 mg-valsartan 320 mg- hydrochlorothiazide 25 mg tablet</i>	6	SYNJARDY 12.5 MG-500 MG TABLET ...	3
<i>amlodipine 5 mg-valsartan 160 mg tablet</i>	6	SYNJARDY 5 MG-1,000 MG TABLET	3
<i>amlodipine 5 mg-valsartan 160 mg- hydrochlorothiazide 12.5 mg tablet</i>	6	SYNJARDY 5 MG-500 MG TABLET	3
<i>amlodipine 5 mg-valsartan 160 mg- hydrochlorothiazide 25 mg tablet</i>	6	SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	3
<i>amlodipine 5 mg-valsartan 320 mg tablet</i>	6	SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	3
FOSAMAX PLUS D 70 MG-2,800 UNIT TABLET	1	SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	3
FOSAMAX PLUS D 70 MG-5,600 UNIT TABLET	1	SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	3
INVOKAMET 150 MG-1,000 MG TABLET	2	<i>triklo 1 gram capsule</i>	5
INVOKAMET 150 MG-500 MG TABLET	2	ULORIC 40 MG TABLET	7
INVOKAMET 50 MG-1,000 MG TABLET	2	ULORIC 80 MG TABLET	7
INVOKAMET 50 MG-500 MG TABLET ..	2	VASCEPA 0.5 GRAM CAPSULE	8
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE	2	VASCEPA 1 GRAM CAPSULE	8
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE	2	<i>zolpidem er 12.5 mg tablet, extended release, multiphase</i>	9
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE	2	<i>zolpidem er 6.25 mg tablet, extended release, multiphase</i>	9
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE	2		
INVOKANA 100 MG TABLET	2		
INVOKANA 300 MG TABLET	2		
JARDIANCE 10 MG TABLET	3		
JARDIANCE 25 MG TABLET	3		
LEVEMIR 100 UNIT/ML SUBCUTANEOUS SOLUTION	4		
LEVEMIR FLEXTOUCH 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN	4		
<i>omega-3 acid ethyl esters 1 gram capsule</i>	5		
<i>risedronate 150 mg tablet</i>	1		
<i>risedronate 30 mg tablet</i>	1		